Antidepressant Relabeling Will Include Pediatric Efficacy Data

FDA's plan for relabeling antidepressants to address pediatric safety concerns will involve some negotiation with sponsors over how best to present efficacy data

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet